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Abstract
Treatment of malignant glioma with chemotherapy is limited mostly because of delivery impediment related to the blood-
brain tumor barrier (BTB). B1 receptors (B1R), inducible prototypical G-protein coupled receptors (GPCR) can regulate
permeability of vessels including possibly that of brain tumors. Here, we determine the extent of BTB permeability induced
by the natural and synthetic peptide B1R agonists, LysdesArg
9BK (LDBK) and SarLys[DPhe
8]desArg
9BK (NG29), in syngeneic
F98 glioma-implanted Fischer rats. Ten days after tumor inoculation, we detected the presence of B1R on tumor cells and
associated vasculature. NG29 infusion increased brain distribution volume and uptake profiles of paramagnetic probes
(Magnevist and Gadomer) at tumoral sites (T1-weighted imaging). These effects were blocked by B1R antagonist and non-
selective cyclooxygenase inhibitors, but not by B2R antagonist and non-selective nitric oxide synthase inhibitors. Consistent
with MRI data, systemic co-administration of NG29 improved brain tumor delivery of Carboplatin chemotherapy (ICP-Mass
spectrometry). We also detected elevated B1R expression in clinical samples of high-grade glioma. Our results documented
a novel GPCR-signaling mechanism for promoting transient BTB disruption, involving activation of B1R and ensuing
production of COX metabolites. They also underlined the potential value of synthetic biostable B1R agonists as selective BTB
modulators for local delivery of different sized-therapeutics at (peri)tumoral sites.
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Introduction
Major advances in medical and surgical treatments in the last
few decades have increased the overall survival of patients with
many types of cancers with the exception of those in the central
nervous system (CNS) [1,2]. In fact, the survival of patients with
malignant gliomas more precisely glioblastoma (WHO grade IV),
the most aggressive and prevalent primary brain tumors in adults
(about 20–30%), has remained virtually unchanged over the last
40 years [3]. Furthermore, analytical epidemiologic studies
indicate that the incidence of these tumors is steadily increasing
in children and adults [4,5]. The cause of this increase in
incidence currently remains unknown. High grade malignant
gliomas (WHO grades III and IV) are characterized by high levels
of proliferative, migratory and invasion activities as well as high
resistance to treatment. These hallmarks typify the aggressive
tumor phenotype and account for the very poor prognosis and as
yet, the incurable nature of the disease. Treatments of patients
with malignant gliomas thus remain palliative and generally
include surgery, radiotherapy, and chemotherapy in various
combinations. Chemotherapy is assuming an increasingly impor-
tant role in the treatment of malignant gliomas [6,7,8].
Chemotherapeutic agents are commonly administered orally or
intravenously [9]. However, these routes of administration do not
provide high concentrations of drugs in the brain parenchyma
especially because of the blood-brain barrier (BBB) that isolates
the brain from the rest of the body [10]. It has been estimated that
only about 2% of drugs pass through this barrier [11,12]. The
impermeability of the BBB is due to tight junction proteins
connecting adjacent endothelial cells, which inhibit any significant
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the endothelial cell membranes also restrain drug transcytosis
across the BBB (see review [13]). The BBB in malignant brain
tumors (also referred to as blood-tumor barrier (BTB)) is abnormal
and variably disrupted within the main body of the tumor and
nearby tissue. Various parts of tumors, especially large areas of
diffuse infiltrative tumors, with a mainly intact BTB may thus be
shielded from chemotherapy [14]. There is thus a critical need to
develop successful methods to safely open the BTB in order to
improve chemotherapeutic treatment for malignant glioma.
Kinins are a group of autacoid peptides formed by numerous
tissues and in the blood at the vascular endothelial layer. They are
natural modulators of the tone and permeability of vessels
including the cerebral microcirculation [15,16]. Bradykinin (BK)
and kallidin (LysBK), and their respective bioactive natural
metabolites (desArg
9BK and LysdesArg
9BK), which lack the C-
terminal arginyl residue, are the main sources of kinin activity.
The biological effects of BK- and desArg
9-related peptides are
mediated through the activation of specific GPCRs called B2R
and B1R, respectively [17]. Like most GPCRs, B2R exhibit
constitutive expression with measurable levels of these receptors
under normal conditions. B2R is thought to be responsible for
most of kinin activities under physiological conditions, including
the regulation of the cardiovascular and kidney functions [17]. On
the other hand, B1R is inducible and is expressed in major
inflammatory pathologies such as cardiovascular diseases and
cancer [17,18], making it an attractive pharmaceutical target with
anticipated reduced collateral effects. B1R is induced or overex-
pressed during tissue injury or ischemia, or following exposure to
bacterial endotoxins or inflammatory cytokines such as interleu-
kin-1b (IL-1b) and tumor necrosis factor a (TNF-a) [18]. Gliomas,
like many other solid tumors, are surrounded by a zone of
inflammation that is needed for sustained tumor growth and
angiogenesis [19,20]. This process is partly dependent on glioma
tumor derived cytokines IL-1b and TNF-a [19,21], which could
plausibly trigger expression and activity of B1R impacting on the
brain tumor microcirculatory system. Preliminary experiments
revealed that tumor F98 gliomas implanted in the brains of rats
have high levels of IL-1b immunoreactivity, providing support to
this hypothesis (Figure S1). Furthermore, in vivo studies on the
effects of exogenous pharmacological agonists and antagonists in a
number of animal disease models have revealed that B1R may
play a role in inducing systemic vascular permeability in peripheral
organs and have been generally supported by semi-quantitative
Evans blue analyses [22,23,24,25,26]. In central nervous tissue,
B1R also appears to modulate BBB permeability, including that of
brain tumors [27,28,29]. This is consistent with preliminary
clinical observations from our group and others showing that
endothelial and glioma cells in human malignant glioma
specimens exhibit B1R immunoreactivity [30,31]. The exact role
of B1R in the glioma biology remains unclear. Although the
evidence so far seems to be pointing to a vasomodulator role of
B1R in the brain tumor vasculature, no clear and convincing
evidence has yet been established.
Based on this rationale, we surmised that selective B1R agonists,
when infused systemically, would induce selective BTB disruption
thereby maximizing macromolecular delivery and efficacy of the
chemotherapeutic agents used to treat malignant glioma. In
addition, agonist treatments would not result in systemic
complications because of the restricted expression of B1R target
in the glioma environnment. We used syngeneic F98 glioma
bearing rats as a clinically relevant animal model of malignant
brain cancer [32,33]. Our objectives were 1) to detect and locate
B1R expression in rat and human brain tumor (for clinical
validation purposes) by integrating molecular and cellular biology
approaches, and 2) to correlate B1R expression to in vivo
functional permeability data of peptide agonists that selectively
target B1R. Previous studies, including ours, have shown that non-
invasive dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI) is a reliable method to determine the spatio-temporal
BTB opening in vivo [34,35,36,37,38,39]. We thus used this
technique with gadolinium-based contrast agents Magnevist (Gd-
DTPA; 0.5 kDa) and Gadomer (17 kDa) as brain intravascular
tracers, together with conventional immunohistochemistry (IHC)
and Evans blue staining of albumin (,65 kDa), to assess the extent
and duration of BTB permeability. We also explored whether a
B1R agonist can enhance bioavailability of the chemotherapeutic
agent Carboplatin (and Magnevist used as reference) in brain
tumor tissues using inductively coupled plasma-mass spectroscopy
(ICP-MS). The natural B1R agonist LysdesArg
9BK (LDBK) and
its degradation resistant, long-acting analogue SarLys[DPhe
8]de-
sArg
9BK, NG29 [40], capable of improved stimulation of BTB
opening, were used for comparison purpose.
Here, we report that NG29, and probably other synthetic
biostable B1R agonists sharing the proper pharmacokinetic
features [40], can be used as selective BTB modifiers to improve
transvascular delivery of various-sized water soluble molecules to
CNS tumors expressing substantial level of B1R. These results
may constitute a significant contribution to the development of
effective systemic chemotherapy modalities for the treatment of
inoperable or of recurrent malignant brain tumors.
Results
Kinin B1R are Overexpressed in Rat Brain F98 Glioma
Tissue, in Human Glioma Cell Lines and in Human Glioma
Specimens
We analysed the expression profile of B1R in rat brain normal
and tumor tissues by RT-PCR and WB (Figure 1A, B). B1R
mRNA and protein expression levels were significantly higher
(p,0.05) in brain tumor tissues than in normal brain tissues. In
fact, most normal tissues had very low to negligible levels of B1R.
To confirm these results and provide an idea of the subcellular
localization of B1R in glioma tissues, we performed standard
peroxidase-based IHC. Glioma tissues and perivascular tumor
microsatellites distant from the primary tumor mass were nearly all
B1R immunoreactive (Figure 1C, ii). Notably, the positive staining
with the anti-B1R antiserum AS434 was mainly intracellular (with
few cell plasma membrane associated labeling) and was confined
to perinuclear zones and inside the nucleus. Closer examination by
high magnification transmission electron microscopy (TEM)
confirmed the predominant localization of B1R to the endoplas-
mic reticulum (ER)/nuclear envelope and nucleoplasm of F98
glioma cells (Figure 1C, vi). Similar TEM results were obtained
with the anti-B1R antibody RC72 (data not shown). We also
detected moderate positive staining in intra- and peritumoral
microvessels (Figure 1) and, sporadically, in ipsy- and contralateral
normal glial cells. Staining was absent or barely detectable in
neurons (Figure 1).
In an initial effort to translate the results from the animal model
to humans, we also examined the expression of B1R in well-
established human glioblastoma cell lines, clinical glioma speci-
mens of varying grades, and post-mortem normal control human
brain biopsies (Figure 2A–D) using the same techniques used to
quantify B1R expression profiles in rats. WB analysis consistently
revealed significantly higher B1R protein expression in glioma
cells relative to their nontransformed counterparts, normal human
astrocytes (Figure 2A). The predominant B1R immunoreactive
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37485Figure 1. B1R expression in normal cerebral cortical and tumoral tissues of F98 glioma-bearing rats. (A) Left: Representative
electropherograms and gel-like images (insets) of RT-PCR products amplified from one tumor and autologous controlateral tissue (normal); LM and
UM correspond to lower and upper internal markers, respectively. Right: Histographic representation of B1R expression from multiple normal and
tumoral tissues. B1R mRNA level was normalized to the corresponding 18S level for each biopsy. n=5 rats. *p,0.05 vs normal. (B) Western blot of rat
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molecular-mass than that identified in rat glioma tissues
(,65 kDa) (Figure 1B), possibly due to differences in post-
translational processing of B1R (ex. glycosylation). The striking
in vitro upregulation was also revealed by RT-PCR (Figure 2B)
and WB analyses (Figure 2C) of B1R in ex vivo human glioma
biopsies. B1R transcripts were variably upregulated in human
grade II-IV astrocytic tumors (9 cases) compared to normal brain
cortical specimens (Figure 2B). WB analyses of a different panel of
tumor tissues (11 cases) confirmed that B1R was expressed in
tumors but not in normal brain tissue (Figure 2C, left panel).
Moreover, WB analyses of protein extracts from seven pairs of
matched human glioma tissues and peritumoral brain tissues
(Figure 2C, right panel) showed that B1R was expressed in all
glioma tissues analyzed while expression levels were variable in the
inflamed peritumoral areas (4/7 cases). The WB results obtained
with AS434 were validated using two other anti-B1R antibodies
(LS799 and RC72), which generated very similar staining patterns
(Figure S2).
Four cases of malignant human astrocytoma specimens that
included one WHO grade 3 and three WHO grade 4 glioblastoma
multiforme, tested positive for B1R expression using the IHC
method (Figure 2D). Like to rat F98 glioma IHC staining, B1R-
positive cells were mainly observed in tumor tissues and were
mostly restricted to the perinuclear envelopes and within nuclei
(Figure 2D). Moreover, B1R immunoreactivity was always
associated with mitotic chromosomes in the anaplastic high-grade
gliomas (Figure 2D, inset), likely due to the localization of B1R in
fragmented endoplasmic reticulum (ER)/nuclear membranes
wrapped around chromatins during mitosis [41]. Microvessels in
malignant tumor also tested positive, albeit to lesser extent
(Figure 2D, black arrowheads), but showed less to no nuclear
staining. On the other hand, one case of benign diffuse low grade
astrocytoma (WHO grade 2) stained negative for B1R (Figure 2D).
These results provide support for the hypothesis that B1R might
be a novel, valid pharmacological target for detecting malignant
astrocytoma, manipulating newly forming vasculature integrity,
and regulating tumor permeability using potent B1R agonists in
preclinical and clinical settings. However, given the small sample
size for human subjects and possible risk of unrepresentative
astrocytoma biopsy sampling related to intratumoral genetic
heterogeneity [42], further work is required to determine the
appropriateness of these results.
The Peptide Agonist NG29 Induces Effective
Transvascular Delivery Across the BTB of Malignant
Glioma and the Accumulation of Two Different-sized
Contrast Agents via B1R and a COX-dependent Pathway
Having shown that B1R are overexpressed in rat brain F98
tumors and its associated blood vascular network, we then used
real-time MRI with two different sized-CA (Magnevist (Gd-
DTPA; 0.5 kDa) and Gadomer (17 kDa)) (Figures 3 and 4) to
determine localization and volume of the tumors and to provide
non-invasive assessment of cerebral microvascular responses and
BTB disruption to the natural B1R agonist LDBK and its
analogue NG29. Magnevist and Gadomer are believed to be non-
toxic, non-actively transported, and are regarded as usefull
intravascular hydrophilic tracers for monitoring paracellular
permeability (via inter-endothelial clefts) and extent of BBB
disruption in vivo [34,43]. The Magnevist-enhanced images
revealed the presence of F98 gliomas as early as 3 days after
their inoculation in rats, with changes in T1 signal intensities that
became much stronger on follow-up through to day 17 (Figure 3A).
This suggested a leaky and penetrable BTB, even during an early
stage of tumor development. The tumor T1-weighted intensity was
isointense with normal brain before injection of CA (data not
shown). Compared with F98-implanted rats, we observed no
Magnevist enhancement at the tumor sites on day 10 post-
inoculation in rats that underwent sham surgery and that were
inoculated with F98-free DMEM (data not shown). The signal
enhancement of Magnevist (Figure 3B, upper panels) and of
Gadomer (Figure 4B, upper panels) was more pronounced in the
central core and the peripheral rim of the tumor relative to
baseline following intracarotid (i.c.) infusion of NG29 (10 nmol/
kg/min for 5 min), which translated to a larger maximum CA
distribution volume (CADV) (Figures 3B and 4A, bottom panels).
In fact, a dose-response relationship and a significantly higher
average maximal CADV were observed with the i.c. NG29-
treated group of animals (Magnevist: 3663%; Gadomer: 2366%)
(Figures 3C and 4B). I.V. administration of NG29 also increased
the total interstitial distribution volume of Gadomer in the tumor
microenvironment but required obviously a higher dose to
produce an effect similar to that seen with i.c. administration,
which creates a rapid ‘‘first pass’’ effect in the brain tumor
(Figure 4B). The increase of mean maximal CADV was not
observed when the vehicle or an equimolar amount of the natural
agonist LDBK was infused (Figures 3C and 4B). The relatively
low-level disruption of the BTB induced by LDBK may be
explained by the activity of kinin-destroying enzymes namely
angiotensin-converting enzyme (ACE,), neutral endopeptidase
24.11 (NEP 24.11), endopeptidases 24.15 and 24.16 (EP24.15
and EP24.16), which are widely distributed in microvessels and in
many tissues including the brain [44].
To investigate which kinin receptor-subtype mediates NG29
responses, the animals were treated with a combination of NG29
and the biostable B1R antagonist R892 [45] or the B2R
antagonist HOE-140 [46] (in dose exceeding twice the agonist
dose) (Figures 3C and 4B). As expected from previous in vitro
selectivity studies [40], only R892 significantly blunted the NG29-
induced increase in mean maximal CADV (Figures 3C and 4B).
To elucidate the mechanism by which NG29 modulates the
disruption of the BTB, we tested two series of inhibitors that block
either the NOS or COX pathway (Figure 4B). The NOS inhibitors
L-NA and L-NAME had no effect on NG29-induced disruption of
brain soluble protein extracts probed with the anti-B1R antiserum AS434. Left: Rat brain tumor shows a robust single immunoreactive band around
60 kD. In the absence of antiserum, no band was seen in the rat brain samples (not shown). Right: Histographic representation of B1R expression
from multiple normal and tumoral tissues. B1R protein level was normalized to the corresponding b-actin level for each biopsy. n=4 rats. *p,0.05 vs
normal. (C) The antiserum used for Western blot was also used to characterize the location of the proteins in rat brain cortical samples by IHC, along
with HRP (panels i–v), and TEM immunogold labeling (panel vi). Photomicrographs illustrating positive B1R immunoreactivity in tumor (C, i–iii) and
microvascular endothelial cells (ii) adjacent to the tumor (black arrowheads). Note the chromosomal staining on all tumor cells under mitosis (black
arrowheads, iii). Negative control with preimmune serum showed no staining (v). Weak positive B1R staining of glial cells from both implanted (ii) and
contralateral hemispheres (iv) is also shown. Magnification as indicated. EM photomicrograph (vi) showing subcellular localization of B1R in a glioma
cancer cell (white arrowheads). Insert: digital enlargement of the delineated area (white rectangle) showing B1R immunoreactivity at both the inner
and outer leaflets of the nuclear envelope. Scale bar=500 nm. Photomicrographs of HRP labeling were equalized in terms of contrast, brightness and
gamma using ImagePro Plus 5.1.
doi:10.1371/journal.pone.0037485.g001
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meclofenamate or indomethacin, two structurally unrelated
COX inhibitors, blocked the effects of NG29 (Figure 4B). This
strongly indicated that COX byproducts (most probably PGI2
and/or PGE2) [15,47,48] play a role in regulating permeability of
BTB. We investigated the reversibility and duration of action of
Figure 2. Overexpression of B1R in human glioma tissues. (A) Detection of B1R in various human glioma cell lines and nontransformed
counterparts, normal human astrocytes, by WB analysis using the anti-B1R antibody RC72. b-actin serves as a loading control in the lower panel. The
doublet band in U138-MG cells may indicate degradation of B1R. (B) Comparative quantification of B1R mRNA levels among normal and glioma brain
tissue samples was normalized against that of the corresponding b-actin. (C) Expression of B1R in normal versus tumoral tissue specimens (left panel)
or in paired primary glioma (T) and peritumoral tissue biopsies (P) (right panel), with each pair obtained from a same patient. Western blot analysis
was performed using the anti-B1R antiserum AS434. (D) Representative images from IHC assay of paraffin-embedded specimens of primary glioma
tissue biopsies (WHO grades II–IV) exposed to pre-immune serum or AS434 antiserum. Optical magnification is indicated in the bottom-right corner
of each image.
doi:10.1371/journal.pone.0037485.g002
Permeabilization of Blood-Tumor Barrier by Kinins
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37485i.c. NG29 by administering Gadomer at different times (3, 60 and
120 min) after the initiation of agonist infusion and determined
mean maximal CADV as described above (Figure 4C). The time-
course results showed that BTB modulatory responses to NG29
promptly peaked at 3 min, remained stable for at least 1 h then
fade away completely after approximatively 2 h, indicating that
the integrity of the BTB had been restored (Figure 4C).
Lastly, increases in CADVs elicited by i.c. NG29 (Figures 3C
and 4B) were associated with increases in the apparent amount of
CA crossing into the brain tumor interstitial space (Figures 3D and
4D). Differences in representative Gadomer concentration–time
plots generated using i.c. NG29 between ipsilateral (tumor-
implanted) and contralateral hemispheres can be appreciated in
Figure 4D (upper panel). The average maximal Gadomer
Figure 3. NG29 enhances transvascular delivery, distribution and accumulation of Magnevist within brain tumor tissues of F98-
bearing rats. (A) MRI contrast-enhanced detection of glial brain tumors in rats at day 3, 5, 7, 10 14 and 17 post-inoculation. Note the rapidly growing
tumor over a 2-week time and the appearance of a necrotic center on the 17 day-image (white arrow) outgrowing its blood supply. Assessment of
BTB disruption by MRI monitoring was conducted on the same animal on day 10 post-inoculation, corresponding to mid stage development of the
tumor. (B) Representative axial Magnevist-enhanced T1-weighted MR images depicting the brain of an F98-implanted rat before and after NG29
treatment (10 nmol/kg/min for 5 min i.c.) (left panel). Note the increase in the signal intensity at the tumor (white arrows). Temporal CADV calculated
from the corresponding sets of images (1 image/51 s for 50 min) (bottom panel). (C) Relative CADV in percent determined following the infusion of
the vehicle (saline), LDBK, NG29 (10 nmol/kg/min for 5 min) or NG29 (10 nmol/kg/min, 5 min) + R892 (20 nmol/kg/min, 5 min). Each bar represents
the mean 6 S.E.M. for 4 to 6 animals. **p,0.01 compared to vehicle-treated animals;
{{p,0.01 compared to NG29-treated animals. (D) Histographic
representation of average maximal Gd-DTPA concentrations in the ipsilateral (tumor-implanted) and the contralateral hemispheres following saline
vehicle or NG29 treatment (10 nmol/kg/min)). Note the superior levels of Gd-DTPA (reflecting greater basal permeability) in the ipsi- versus
contralateral tissues of vehicle-treated animals (not illustrated, ***p,0.001). **p,0.01 compared to vehicle-treated ipsilateral groups. Value
represents the mean 6 S.E.M. obtained with 3 animals.
doi:10.1371/journal.pone.0037485.g003
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37485Figure 4. NG29 increases transvascular delivery, distribution and accumulation of Gadomer within brain tumor tissues of F98-
bearing rats. (A) Representative axial Gadomer-enhanced T1-weighted MR images depicting the brain of an F98-implanted rat before and after
intracarotid NG29 treatment (10 nmol/kg/min for 5 min i.c.) (upper panels). Note the increase of the signal intensity at the tumor (white arrows).
CADV in function of time calculated from the corresponding set of images (1 image/51 s for 50 min) (bottom panel). (B) Dose-, B1R-, PGs-dependence
of NG29-induced BTB permeability. Numbers in parenthesis represent infusion rates in nmol/kg/min, for 5 min. The B2R antagonist HOE140 and the
B1R antagonist R892 (both at 20 nmol/kg/min, for 5 min, i.c.) were infused simultaneously with NG29 while the non-selective nitric oxide synthase
(NOS) inhibitors L-NA (5 mg/kg, i.v.) and L-NAME (20 mg/kg, i.v.), and the non-selective cyclooxygenase (COX) inhibitors Meclofenamate (5 mg/kg,
i.v.) and Indomethacin (2.5 mg/kg, i.v.) were administered 30 min before the infusion of NG29. Note the effectiveness of NG29 administered by the i.v.
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compartment significantly exceeded that of control untreated
group (Figure 4D, bottom panel). Similar results were obtained
with Magnevist (Figure 3D). There was no tendency of increased
Gadomer concentration over time in the contralateral hemisphere
and the jaw muscle upon NG29 treatment, demonstrating the
tumor-site specific activity of NG29 (Figure 4D).
Comparison between the Intracerebral Delivery of
Magnevist and Carboplatin Following Intraarterial or
Intravenous NG29 Administration
To corroborate the contrast-enhanced MRI findings and to gain
better insights into the potential of B1R agonists for delivering
chemotherapeutic agents into CNS tumors via different routes of
administration, we used the validated, highly sensitive, elemental
ICP-MS method. We determined the Carboplatin platinum and
Magnevist gadolinium content of tissue extracts from tumor,
adjacent brain tissue, and cortical contralateral tissues (Figure 5).
Even though it is known that F98 glioma cells are highly resistant
to DNA-alkylating agents such as Carboplatin [49], we chose to
study this chemotherapeutic agent because it is used to treat
glioma patients, albeit with limited evidence of efficacy [50]. Its
molecular size (371 Da) and hydrophilicity are comparable to
Magnevist (500 Da). As such, we anticipated that its intracerebral
bioavailability would be similar to that of Magnevist. Our results
proved the hypothesis and showed that the systemic co-adminis-
tration of NG29 with Magnevist and Carboplatin significantly
enhanced their brain delivery and actual bona fide concentrations,
to a similar degree, in tumor and peritumoral sites (,2-fold
increase in both cases) (Figure 5). Notably, the NG29/drug
combination can be given i.v. or i.c. with similar effectiveness,
taking into account dosage adjustement for difference on the
administration site of the mixture. We observed no consistent
changes in Magnevist or Carboplatin concentrations in the
contralateral control side after systemic i.v. and i.c. NG29
administration (Figure 5). In fact, drug concentrations in
contralateral tissues felt to negligible levels (# 5%) as compared
to tumoral tissues from CTL and NG29-treated animals.
NG29 Increases BTB Permeability and the Uptake of
Large Protein Albumin by Rat Gliomas and Peritumoral
Tissues
We then looked at whether albumin (,65 kDa), which is a
larger molecule than the CA, could also be delivered to tumor sites
by modulating BTB permeability with NG29. Many chemother-
apeutic agents (eg, chlorambucil, etoposide, melphalan, vincris-
tine, and paclitaxel) are heavily bound (.90%) to plasma proteins,
unabling them to cross the BBB [10]. We thus reasoned that it
might be worthwile to use synthetic B1R agonists to facilitate local
entry of albumin-bound drugs given that the bound fraction will
probably be released into brain tumors in order to maintain
equilibrium. We used macroscopic direct albumin immunostain-
ing and EB-staining methods to assess albumin uptake. The results
of these experiments are presented in Figure 6 (A and B). Positive
albumin immunoreactivity can be seen in brain regions surround-
ing tumors in control animals, indicating the presence of
inflammatory BBB damage (Figure 6A, left upper panel). We
observed an increase in extravasated albumin staining in the
implanted hemisphere following disruption of the BTB with i.c.
NG29 (50 nmol/kg/min for 5 min), with the periphery of tumor
having more marked staining than the central portion (Figure 6A,
center upper panel). The presence of high interstitial fluid pressure
in the core of tumor most likely explains this phenomenom. No
staining was observed in control (not shown) and agonist treated
sections using the antibody preabsorbed with purified rat albumin
antigen (20-fold excess), demonstrating the specificity of the
staining patterns observed (Figure 6A, right upper panel). Both
the surface area and the intensity of albumin immunostaining
(expressed as total IOD) at tumoral sites increased in response to
i.c. NG29 (Figure 6A, left and right bottom panels). The co-
injection of i.v. NG29 with the albumin-binding dye Evans blue
caused brain tumor-specific accumulation of the dye (Figure 6B),
suggesting that i.v. administered NG29 homes to brain tumors by
initially binding to B1R that are specifically expressed on tumor
microvessels. As shown by the IHC staining of albumin, the local
induction of plasma albumin extravasation by NG29 was more
localized at the invasion site (referred to as BAT) than at the tumor
itself (approximatively 2- versus 1.5-fold increase, respectively).
No significant changes in mean arterial blood pressure, heart
rate, respiratory rate, or body temperature were observed
following the administration of NG29, regardless of administration
route and dosing regimen (Figure S3). Hematocrit and arterial pH
values also remained in physiological ranges at 1 h post-NG29
administration (data not shown). Thus, the pharmacological
modulation of BTB with NG29 agonist appeared to be safe and
secure. The apparent lack of toxicity of NG29 was supported by
the results of preliminary toxicity analyses consisting of repeated
daily bolus injections of single suprapharmacological dose of the
peptide NG29 (50 mg/kg, i.v. tail-vein) over a period of three days
in normal Fischer rats. Except for a mild elevation of body
temperature (control: 3761 vs treated 3961Cu), which disap-
peared within few hours (possibly mediated by central release and
action of propyretic prostaglandins (Figure 4B)), NG29 had no
toxic effects (data not shown).
Taken together, our results show that B1R agonism may be a
valuable therapeutic approach for increasing the selective pene-
tration into brain tumors of systemically administered chemother-
apeutic drugs or tumor-imaging agents that otherwise have no or
limited access to this region. Cognate agonists that are not
metabolized in the bloodstream and that temporarily increase
BTB permeability may thus be potential adjuvants for optimizing
the performance of anticancer drugs used in the treatment of
malignant brain cancers.
Discussion
The salient findings of our study can be summarized as follows:
1) intracranial F98 glioma tumors expressed B1R mRNA and
protein; 2) B1R mainly localized in tumor cells (especially in the
(intrajugular) route.
+p,0.05 compared to vehicle-treated animals; *p,0.05 compared to NG29 (10 nmol/kg/min)-treated animals. (C) Duration of the
increase in BTB permeability caused by NG29 as detemined by relative CADV values. Gadomer was injected 3 min, 60 or 120 min following the start
of the infusion (10 nmol/kg/min) of NG29 over 5 min. Each bar represents the mean 6 S.E.M. for 3 to 7 animals. *p,0.05 compared to respective
vehicle-treated animals. (D) Representative time course of Gadomer uptake in the ipsilateral (tumor-implanted) hemisphere and the contralateral
hemisphere, before and after treatment with NG29 (10 nmol/kg/min for 5 min) (left panel). Histographic representation of average maximal Gadomer
concentrations in the ipsilateral (tumor-implanted) and the contralateral hemispheres, and the facial muscle following NG29 treatment (right panel).
As observed for Gd-DTPA, levels of Gadomer were higher in the ipsi- (tumors) than in contralateral (normal) tissues in CTL animals (not illustrated,
***p,0.001). *p,0.05 compared to untreated (Gadomer alone) ipsilateral groups. Value represents the mean 6 S.E.M. obtained from 3 animals.
doi:10.1371/journal.pone.0037485.g004
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administration of the metabolically stabilized desArg
9-bradykinin
analogue, NG29, but not the natural agonist LDBK, promoted
B1R-mediated transvascular delivery of hydrophilic low- and high-
molecular weight soluble macromolecules (Magnevist, Gadomer,
Carboplatin and endogenous albumin) through the BTB and their
accumulation in tumors; 4) the single permeation of the BTB with
NG29 was reversible, was effective by i.v. or i.a. infusion, operated
via a COX-mediated mechanism, and appeared relatively safe;
and 5) importantly, various human glioblastoma cell lines and
Figure 5. NG29 induces changes in local concentration of gadolinium and platinum in tumoral cerebral tissues. Direct measures of
drug concentration (ng/g of tissue) by ICP-MS in three different tissue extracts (tumor, tumor periphery and contralateral) from the brain of F98
glioma-bearing Fischer rats were made following intraarterial (carotid artery) or intravenous (femoral vein) injections of Gd-DTPA (Gd) (143 mM i.v.)
and carboplatin (Pt) (20 mg/kg i.a. or i.v.) with the B1R agonist NG29 (250 nmol/kg i.a.; 5 mmol/kg i.v.) or saline (CTL). Note the difference in ordinate
scaling between drug concentrations in contralateral and tumoral tissues. Data are mean 6 S.E.M. of 7–10 rats in each group. *p,0.05 versus
respective control; N.S.: non significant.
doi:10.1371/journal.pone.0037485.g005
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B1R expression compared to their normal cellular/tissue coun-
terparts, identifying the B1R as a potentially relevant biomarker
and therapeutic target for brain cancer. Our findings offer
preclinical proof of principle that targeting B1R in the brain
tumor microenvironment can be a highly effective approach for
delivery of chemotherapeutic agents.
Much effort has gone into identifying powerful and selective
methods to bypass or transiently breach the BBB/BTB that could
be used in chemotherapy protocols [51,52]. For instance, the
Figure 6. Systemic infusion of NG29 increases permeability and uptake of albumin within peritumoral tissue. (A) Direct immunological
staining of endogenous albumin in brain tissues from F98-implanted rats treated or not with intracarotid NG29 (50 nmol/kg/min for 5 min).
Representative coronal sections of CTL-, vehicle- and NG29-treated rats immunostained with sheep anti-rat albumin HRP conjugated are shown in the
upper panels. Scale bar: 1 mm. Histographic representation of integrated optical density (IOD) values (left) and stained surface areas (right) of
immunoreactive albumin in respective animal groups (bottom panels). ***p,0.001 vs CTL. (B) Semi-quantitative measurement of Evans blue content
(mg/g wet weight tissue) in several tissues after systemic intravenous (femoral) injection of saline vehicle or NG29 (5 mmol/kg i.v.) in F98 glioma
bearing rats. Data are presented as means 6 S.E.M. n=5 to 7 animals per group. *p,0.05 vs respective vehicle group.
doi:10.1371/journal.pone.0037485.g006
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receptor-mediated transport mechanisms (known as transcytosis)
are possible methods for enhancing drug targeting to brain
tumors. However, the clinical benefit of these aproaches has yet to
be proved [51,52]. Other methods to open the BBB/BTB via the
paracellular pathway such as the intracarotid infusion of
hyperosmolar mannitol or Cereport (Labradimil and formerly
called RMP-7), a selective bradykinin B2R agonist, have been
shown to be safe, with no associated vasogenic brain edema and
apparent neurocognitive function loss, and effective in the
adjuvant treatment of experimental and clinical brain tumors
[10,11,53,54]. However, both techniques have a number of
disadvantages. The osmotic BBB disruption procedure using
mannitol is cumbersome and highly invasive, requires general
anesthesia, permeabilizes the normal BBB, thus is not fully
compatible with certain classes of chemotherapy that are
neurotoxic (e.g. taxanes, doxorubicin, cisplatin), and carries a risk
of inducing seizures [10]. The BK-B2R-mediated BTB opening
using Cereport is transient and lasts only 20 min, even with
continuous infusion of the agonist. In addition, it does not work
when the agonist is i.v. administered [14]. Cereport also has a
narrow therapeutic index and a number of adverse effects, mainly
vasodilatation and decreased blood pressure, which limit its
practical value [14,54].
We provide a new mechanistic insight into the design of
minimally invasive pharmacological method for inducing local,
transient BTB permeability to enhance transvascular transport of
drugs intended to detect (namely MRI agents) and to treat brain
cancer, thus paving the way for earlier diagnosis and more
targeted treatments. The method relies on systemic co-adminis-
tration of potentially safe, fast acting, synthetic peptide agonists
such as NG29 [40] that trigger kinin B1R activity at brain tumor
sites. We believe that synthetic biostable peptide B1R agonists,
when used as BTB permeability enhancers, may offer a number of
potential advantages over other strategies including a) unsurpassed
affinity/potency towards human B1R [40], b) expected good
safety profile due to their high selectivity and specificity [40], c) a
negligible immunogenicity, as with other kinin related peptides of
similar size such as Icatibant [55], Cereport [54] and R954 [56]
(Sirois P, personal communication), d) a high therapeutic index
due to the localized expression of B1R in tumors (Figures 1, 2 and
5) (B1R has virtually no role in normal physiology), e) a lack of
tachyphylaxis by receptor desensitization upon agonist exposure
[17], which may explain why the BTB-permeability effects of B1R
agonists lasted considerably longer than those of the B2R agonists
BK and Cereport (Figure 4), f) may not require surgery and
general anesthesia if given i.v., and g) do not require chemical
modifications to deliver the drug in the CNS.
In addition, our findings showed that there is concordant high-
level expression of (vascular and tumoral) B1R on malignant
tumors in the preclinical F98 glioma xenograft model (Figure 1), in
various human glioblastoma cell lines and in clinical glioma
samples (Figure 2), as shown by our RT-PCR, WB, and IHC
results. It is to be noted that the high prevalence of B1R protein
expression we observed in malignant glioma patient samples may
occasionnaly extend to adjacent peritumoral brain regions
(Figure 2C), possibly due to the presence of infiltrative tumor
cells. Our initial validation of B1R targets in actual high-grade
human glioma cells and tumor microvessels underlines the need
for further research to assess the potential of B1R agonists in the
diagnosis and/or adjuvant chemotherapy of brain tumors.
Determining expression levels of expression in human high-grade
glioma biopsies may also be valuable for the early prediction of
treatment responses to B1R agonists that modulate BTB
permeability.
We used high-field MRI to show that the B1R agonist NG29
can induce rapid transvascular delivery and uptake increment
(about 1.5-fold higher) of both Magnevist (0.5 kDa) and Gadomer
(17 kDa) into intracerebral F98 glioma in syngeneic Fischer rats,
as shown by the increase of T1 MRI intensity signals (Figures 3 and
4). It should be noted that the areas of BTB disruption following
intracerebral injection of NG29 corresponded closely with the
distribution of B1R in the tumor (Figure 1). Similar efficacy data of
NG29 were obtained using a syngeneic rat model of intracerebral
metastatic breast cancer (a secondary brain tumor model) with an
impeded BTB [57] (Figure S4). The sizes of these MRI agents
cover the spectrum of molecular weights of most commonly used
antineoplastic agents [9,52].
Systemic co-administration of NG29 also improved brain tumor
uptake profiles (2-fold) of i.v. or i.a. Carboplatin (Figure 5), which
is in agreement with the MRI results (Figures 3 and 4). This is in
the same range of increase of [
14C]-Carboplatin levels induced by
ic Cereport in RG2 brain tumors [58]. Our results also indicated
that NG29 opens the BTB wide enough to allow free and Evans
blue bound-albumin (,65 kDa) to cross the BTB (Figure 5). Good
brain tumor penetration of drugs of comparable or smaller
dimensions can thus be expected. For instance, B1R agonists could
conceivably be used as an add-on treatment to improve glioma
immunotherapy aimed at artificially priming the immune system
with specific cytokines (ex. IL-12, IFN-b, TNF-a, etc.) that
promote antitumor T-cell activity [59,60], as previously proposed
for the selective B2R bradykinin analogue Cereport [61].
Combining B1R agonist with different anticancer drugs may be
particularly useful in a multipronged ‘‘cocktail’’ attack of brain
tumor cells, which is the gold standard of modern clinical trial
designs [62]. However, further work is required to confirm this
hypothesis. Overall, our findings demonstrate that the B1R agonist
NG29 can be administered i.a. and i.v. in dosages that create
preferential extensive extravasation of various drugs in the glioma
microenvironment (including central and peripheral portions)
while not disturbing the integrity of normal microvessels of organs,
such as the normal brain, lung, pancreas, kidney, muscle, skin,
heart, liver, and of macrovessels (aortae) (Figure 6). This may be
particularly relevant with regards to increasing therapeutic
delivery within and most importantly, beyond the edge of the
primary tumor in order to gain access to infiltrated tumor foci.
As mentioned, drugs penetrate the BBB/BTB via the para-
cellular tight junctional and transcellular vesicular pathways,
among others [13]. Since albumin and the two CA used in the
present study are apparently not transported across the BBB/BTB
via any known transcellular pathway, these results would suggest
that NG29 mediates the increase in cerebrovascular permeability
mostly through a paracellular mechanism. However, in the
absence of in vivo results from tests with specific markers of
transcellular permeability such as transferrin, insulin, and amino
acids [13], it is possible that NG29 increases both paracellular and
transcellular permeation across the BTB. Other experiments will
be required to clarify this issue.
We have partially deciphered the mechanism underlying the
NG29-induced increase in BTB permeability and the delivery of
drugs to brain tumors. This may involve direct activation of the
B1R at the tumor vasculature causing i) increased blood flow
(hyperemia) through arterial/arteriolar vasodilatation, ii) increase
in venular tone (venocontriction) leading in both cases to a rise in
capillary hydrostatic pressure and/or iii) increased capillary/
venule permeability by retraction (fenestration) of the endothelial
cells. All of these events may cause in turn, disengagement of tight
Permeabilization of Blood-Tumor Barrier by Kinins
PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e37485junctional zones in capillaries/venules and contribute to the
opening of the paracellular pathway [29,63]. In addition, since
glioma cells overexpress B1R (Figures 1 and 2) and can secrete
capillary permeability factors such as arachidonic acid when
activated [64], we cannot exclude the possibility of an indirect
mechanism of NG29 passing through the BTB and acting on these
cancer cells in the induction of BTB opening, much like the B2R-
mediated increase in BTB permeability caused by Cereport
[65,66]. Future studies are necessary to elucidate the exact
mechanism(s) responsible for the tumor hyperpermeability re-
sponses to NG29. However, our results provide convincing
evidence that secondarly released prostanoids play a key role
given that pharmacological inhibition of the COX pathway, but
not the NOS pathway, repressed NG29 activity. This contrasts
with the B2R-mediated increase in BTB permeability in RG2 or
F98 glioma-bearing rats, which mainly depends on NO produc-
tion [34,67].
As already emphasized for Cereport [68] and mannitol [53], the
rate and duration of agent infusion, among other parameters, are
to be considered critical factors for successful BTB disruption.
Experiments are underway to determine whether prolonged
infusion of NG29 could extend much further the opening period
of time and retard recovery (closure) of the BBB/BTB. Because of
absence of ligand-induced desensitization of B1R [17], a
prolongation of signalling pathway initiating endothelial retraction
or inhibition of intercellular adhesion may be anticipated. These
experiments will most likely be necessary to establish an optimum
dosing paradigm and improve therapeutic efficacy. Agonizing the
B1R with NG29 to tackle the porosity-permeability problem of the
BTB appears relatively safe as there was no abnormality evidence
of some forms of hemodynamic and respiratory instabilities. This
is in marked contrast with the earlier approach using metabolically
protected agonists to activate B2R in order to manipulate the BTB
[14,69]. In fact, under the same experimental conditions, we
observed severe undesired effects (non-specific permeability
induction, disturbance of respiratory function, hypotension) when
the pseudopeptide B2R agonist R523 ([Phe
8y(CH2NH)Arg
9]-BK)
[34,70] was used at the same dose as NG29 (50 nmol/kg/min for
5 min, i.c.) (Figure S4).
One possible concern about the use of exogenous selective B1R
(or B2R) kinins as BTB disruptors in adjuvant glioma therapy is
that they can potentially act as mitogens with pro-migratory
activity (at least in vitro) and may thereby accelerate disease
progression [71,72,73]. However, some evidence argues against
this possibility. First, the proliferation rate of F98 cells cultured in
vitro in the presence of LDBK or NG29 (10 mM) over a 96-h
exposure period was the same as the control untreated cells, as
determined with the MTT and crystal violet colorimetric methods
[74] (Figure S5A). Second, and more convincingly, the median
and maximum survival of F98 glioma bearing rats following i.a.
and i.v. infusion of NG29 at maximal doses tested were the same
as those of the vehicle-treated animals (Figure S5B). This is in
agreement with the findings of similar survival studies in
orthotopic brain tumor xenograft models that used the selective
kinin B2R agonist analogue Cereport, which had no growth
stimulatory effects on brain tumor cells in vivo (see reviews,
[14,54]).
Lastly, one unanticipated finding of the study was that the B1R
are predominantly expressed internally, mainly at the nuclear
envelope, in in situ high-grade rat and human glioma tumors
(Figures 1 and 2). Elevated B2R levels in the nucleus have recently
been documented in the F98 rat glioblastoma model [34].
Elevated nuclear B1R and B2R levels have also been reported
in other types of cancer such as malignant pleural mesotheliomas
[75] and lung cancer [76]. An emerging concept in the field of
GPCRs is that these receptors can function intracellularly on ER/
nuclear membranes to promote noncanonical actions in normal
physiological as well as disease states [41,77,78,79,80]. Whether
B1R located at the ER/nuclear envelope can mediate intracrine
regulation of oncogenic pathways associated with aberrant growth,
invasion and survival processes of glioma cells are subjects of
investigation in our laboratory.
In conclusion, our results document a novel GPCR signaling
mechanism for promoting transient BTB disruption to F98 rat
glioma, involving activation of B1R and ensuing production of
COX metabolites. Our results also underline the potential value of
synthetic B1R agonists as selective BTB modulators for increasing
the local delivery of various sized-therapeutic agents to (peri)tu-
moral sites. Combining chemotherapeutic agents with a B1R
agonist may thus be a valuable strategy for improving the
effectiveness of the agents against malignant gliomas while possibly
minimizing systemic exposure.
Materials and Methods
Solid Phase Peptide Synthesis
























(HOE140), were synthesized on a Pioneer peptide synthesizer
using the Fmoc (9-fluorenylmethyoxy-carbonyl) solid-phase chem-
istry as previously described [40,70]. Peptide purity (.95%) was
assessed by analytical RP-HPLC, and molecular weights were
verified by electrospray mass spectrometry using a VG Platform ns
8230E (Waters). Binding affinity (transiently transfected HEK-
293T cells) and pharmacological activity (contraction of isolated
human umbilical veins) of the peptides on human B1R expressing
systems were in agreement with previously reported data from our
laboratories, indicating a high level of batch-to-batch consistency
[40,45,70]. Peptides were stored in powder form at 220uC. Stock
solutions (10 mM) of peptides were also prepared in Nanopure
water and were stored at 220uC until use. The stock solutions
were diluted in sterile 0.9% saline prior to each experiment.
Animals
Male Fischer 344 rats (250–275 g, Charles River Laboratories,
St-Constant, Que ´bec, Canada) were used. Animals were used in
full compliance with the Canadian Council of Animal Care
guidelines. The protocol was approved by the Committee on the
Ethics of Animal Experiments of the University of Sherbrooke
(CIPA/CFPA-FMSS).
Clinical Samples
Fresh human brain tumor tissues were obtained from 41
patients (26 males and 15 females, aged 21–75 years) who
underwent therapeutic removal of astrocytic brain tumors between
2004 and 2009 at the Centre Hospitalier Universitaire de
Sherbrooke (CHUS). Whenever possible, peritumoral brain
samples (comprising infiltrative astrocytomas and normal brain
tissues) were also collected. Most specimens were obtained at
primary resection. All glioma specimens were classified morpho-
logically and graded by an experienced neuropathologist (AMT),
as per WHO criteria. One astrocytoma WHO grade 2 (from a 67
year male) was purchased from BioChain. Post-mortem human
brain (frontal or temporal) cortex tissues from white males aged
between 36 to 62 years old who had met sudden death resulting
from either cardiac arrest (1 case), drowning (1 case), or
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Brain collection (Maryland Psychiatric Research Center, Balti-
more, MD, USA) and were used as controls. The resected tumors
or normal brain tissue specimens were snap-frozen in liquid
nitrogen and were stored at 280uC until used for RNA and
protein extractions. Other tumors were fixed in 10% buffered
formaldehyde for ,24 h, embedded in paraffin, cut into 3-mm-
thick sections, and mounted on silanized slides. For histological
confirmation, the sections were stained with haematoxylin and
eosin. Written informed consent was obtained from all study
participants. The study was carried out with the approval of the
research ethic board for human subject of the CHUS.
Cell Lines and Cultures
The established human glioma cancer cell lines U87-MG
(#HTB-14), U138-MG (#HTB-16), U118-MG (#HTB-15),
T98G (#CRL1690), LN-229 (#CRL2611), and the F98 rat
glioma cells (#CRL-2397) were purchased from American Type
Culture Collection (ATCC). These cells were cultured as
monolayers in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin-streptomycin mixture at 37uC in a humidified 5%
CO2/95% air incubator.
Glioma Cell Implantation
The procedure of F98 glioma cell implantation was similar to
that used in our previous studies [33,34]. Briefly, F98 glioma cells
(1610
4 cells in 5 ml) were injected into the region of the right
caudate nucleus of the animals under ketamine: xylazine
anesthesia (87 mg/kg:13 mg/kg, i.p.) at the following stereotaxic
coordinates: 1 mm anterior and 3 mm lateral to bregma, and
6 mm below the external table of the skull. Unless otherwise
specified, tumors were allowed to grow for 10 days to mid-stage
(approximately 15–20 mm
3) before the beginning of the experi-
ments. All tumor transplantations were successful as determined
by histology and/or MRI.
RT-PCR
The rats were anesthetized with 2% isoflurane and were
transcardially perfused with 60 ml of phosphate-buffered saline
(PBS; 0.01 M phosphate-buffered 0.9% NaCl solution, pH 7.6).
Brain tumors and control autologous tissues from the contralateral
hemisphere were resected from the brains. Resected samples were
snap-frozen in liquid nitrogen and were stored at 280uC until use.
RNA was extracted and reverse transcribed as previously
described [34]. The oligonucleotide primers for amplifying the
kinin rat B1R and 18S (internal control), and the length of the
expected PCR products (in parentheses) were as follows: B1: F 59-
ACT GTG TCA ACG TCA GGT CAC TGT-39,R5 9-GAT
GCT GAC AAA CAG GTT GGC CTT-39 (431 bp); 18S : F 59-
GTG CAT GGC CGT TCT TAG TTG GTG-39,R5 9-CCA
TCC AAT CGG TAG TAG CGA CGG-39 (401 bp). Amplifi-
cation reaction mixtures contained 1x amplification buffer,
1.5 mM MgCl2, 10 mM dNTPs, 400 nM primers, and 1 U of
Platinum Pfx DNA polymerase (Invitrogen, Canada). As a
negative control, reverse transcriptase was omitted during the
initial cDNA synthesis step. The PCR products were quantified
using the DNA 1000 kit for the Agilent 2100 Bioanalyzer (Agilent
technologies) [34].
Western Blot
Brain tumors and control autologous subcortical tissue taken
from the contralateral hemisphere were resected from the brains
under the same conditions as above. Total protein extraction from
tissues were prepared by adding RIPA buffer (50 mM Tris–HCl
pH 7.4, 150 mM NaCl, 1% NP40, 0.25% deoxycholate, 1 mM
EDTA, 1 mM Na3VO4, 1 mM NaF) containing a protease
inhibitor cocktail (Roche, Canada). Brain samples were disrupted
using a Potter homogenizer and left on ice for 15 min. Tissue
extracts were sonicated twice for 10-sec bursts on ice and then
centrifuged at 16,000 g for 15 min at 4uC. Whole-cell lysates were
also prepared from semi-confluent human glioma cell line cultures.
A lysate of primary normal human astrocytes (NHA) purchased
from Sciencell Research Laboratories (Carlsbad, CA) was used as
a control. Proteins were quantified using BCA
TM (bicinchoninic
acid) protein assay kits (Pierce). SDS-PAGE and Western blotting
(WB) were performed as previously described [80]. The following
primary antibodies and dilutions were used: rabbit anti-B1R
antiserum (mix AS434:0.2 mg/ml; 1:5,000) (provided by
Dr. W Mu ¨ller-Esterl, University of Mainz, Germany) and mouse
monoclonal anti-b-actin antibody (1:20,000, Sigma-Aldrich).
Rabbit anti-mouse (1:20,000, Sigma-Aldrich) or sheep anti-rabbit
(1:10,000; Serotec) antibody conjugated to horseradish peroxidase
was used as secondary antibody. The same techniques were used
to extract total proteins from human normal brain and glioma
samples for WB. B1R expression was quantified using ImagePro-
Plus 5.1 and was normalized against b-actin expression level. The
specificity of the antiserum to B1R (raised against intra- and extra-
cellular domains of the human B1R sequence) has been reported
elsewhere [70]. On some occasions, the staining pattern seen with
the AS434 antiserum was confirmed using two other polyclonal
anti-B1R antibodies (recognizing C-terminal domains), namely
LS-A799 (1:1000, LifeSpan) and RC72 (1:300; a kind gift of
Dr. R Couture, Universite ´ de Montre ´al, Canada).
Immunohistochemistry
F98-implanted rats were deeply anesthetized with ketamine:
xylazine on day 10 and were then perfused with PBS, followed by
4% formalin solution. Brains were carefully removed, post-fixed
overnight in 4% formalin. A 5-mm-thick coronal brain slice
containing the tumor was paraffin embedded, and 3-mm-sections
were mounted on positively charged slides for immunochemical
localization of B1R. IHC staining was performed with an
automated system (Dako Autostainer plus) using the Envision
Flex High pH visualization system (Dako). The mix anti-B1R
antiserum (AS434) was diluted 1:800 in blocking buffer and
incubated on the brain slides 1 h at room temperature. After
washing, secondary sheep anti-rabbit antibody-HRP (1:100)
(Serotec) was added for 1 h at room temperature. Diaminoben-
zidine (DAB) (Roche) was used as chromogen. Nuclei were
counterstained with hematoxylin. An identical IHC staining
protocol was used for the human normal brain and glioma
biopsies. All the slides were observed under light microscopy
(Olympus model BX51). For high-resolution transmission electron
microscopy (TEM), tissue samples were processed according to
standard techniques [80]. Ultrathin epoxy-embedded sections
(,50 nm) were collected on formvar-coated nickel grids and were
immunolabelled with AS434 (1:20). The grids were then incubated
with a goat anti-rabbit gold (10 nm)-conjugated IgG (1:20) (Sigma-
Aldrich) without silver intensification. The sections were then
examined using a transmission electron microscope at 120 kV
(Hitachi, H-7500). Sections treated with normal (preimmune)
rabbit serum were used as negative controls.
BTB Permeabilization Procedure
The experimental protocol was similar to that used in a previous
study [34]. The animals were anesthetized using isoflurane gas
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performed on a heating pad to avoid per-procedural hypothermia.
The caudal vein was catheterized to enable the injection of CA via
PE-10 intramedic tubing later connected to a remote-controlled
power injector (model PHD 2000, Harvard Apparatus). The right
carotid complex was surgically exposed and the external carotid
artery was catheterized in a retrograde fashion using PE-50
intramedic tubing such that the tip of the catheter lay just above
the bifurcation. This catheter was used to infuse drugs directly into
the right hemisphere of the brain via the internal carotid. For the
BTB permeabilization procedure, the animals received a single
intracarotid infusion of vehicle (sterile 0.9% saline), B1R agonist
(LDBK or NG29) (2.5, 10 or 50 nmol/kg/min for 5 min) alone, or
NG29 in combination with antagonists for B1R (R892) or B2R
(HOE140) (20 nmol/kg/min for 5 min), during MRI scans (see
below). Total volume infused was kept constant at 0.5 ml. In other
experiments, animals were pretreated with non-selective nitric
oxide synthase (NOS) inhibitors (L-NA (5 mg/kg) or L-NAME
(20 mg/kg) (Sigma-Aldrich)) or with non-selective cyclooxygenase
(COX) inhibitors (Meclofenamate (5 mg/kg) or Indomethacine
(2.5 mg/kg) (Sigma-Aldrich)). These inhibitors were given i.v. as a
bolus with a 150 ml saline flush via the caudal vein, 30 minutes
prior to intracarotid NG29 infusion (10 nmol/kg/min for 5 min).
All the inhibitors were dissolved in isotonic saline, except
indomethacine, which was dissolved in 75% ethanol prior to
dilution. The doses of the inhibitors were selected based on results
of previous studies. In some cases, NG29 was also administered via
the intrajugular route by a catheter pre-inserted through the right
internal jugular vein. Arterial blood pressure was monitored
throughout the experimental period with a blood pressure monitor
(DigiMed) using the catheter surgically inserted into right femoral
artery.
MRI and Data Post-processing
MRI studies were conducted at the Centre d’Imagerie
Mole ´culaire de Sherbrooke using a Varian 7T small animal
scanner (Varian Inc.) equipped with 210/120 mm gradient coils
(30 G/cm) and a 63-mm volume RF coil. All MRI measurements
were performed according to Co ˆte ´ et al. [34]. For the MRI
experiments, the animals were anesthetized with 2% isoflurane
(Abott) administered with a face mask. The temperature in the
scanner was kept constant at 30uC (with rectal temperature
remaining near 37uC) using a warm-air heating system (SA
Instruments). Thirty sets of T1-weighted images were acquired
continuously before, during, and after CA injection with a
temporal resolution of ,51 s using the following parameters:
TR=100 ms, TE=2.49 ms, a=30u, matrix=1286128, field of
view (FOV)=35635 mm
2, number of averages=4, and ten
contiguous 1.5- mm-thick slices. The MRI experiments were
performed in two sessions (without and then with BTB
permeabilization procedure) for each animal. This study design
allows each animal to act as its own control. The first MRI session
was performed with a bolus injection (3 min after the first of 30
scans) of either Magnevist (Gd-DTPA, 0.5 kDa) or Gadomer
(,17 kDa) (143 mM in 500 ml, 1 min duration) (Bayer Schering
Pharma AG, Germany) in the lateral tail-vein to determine the
extent of BTB permeability in and around the intracranial tumor.
The second MRI session was performed using a bolus injection of
the same CA immediately following the permeabilization of the
BTB with a B1R agonist (see above). The time lags between
sessions were 4 h for Magnevist and 12 h for Gadomer. These
time lags were selected to ensure complete elimination of the CA
from the brain circulation [34].
The image data was processed using MATLABH (The Math-
Works, 2007). Both sets of anatomic MR images were analyzed for
the presence or absence of contrast enhancement within and
surrounding the tumor areas, and were processed to yield
quantitative contrast agent distribution volume (CADV; in
mm
3), which was used as an index of vascular permeability [34].
The relative CADV expressed as a percentage is defined as the
normalized ratio between the maximal CADV value determined
from the second set of images acquired (CA + BTB permeabiliza-
tion procedure) and the maximal CADV value determined from
the first set of images (CA alone). In separate analyses, the MRI
signals were calibrated in terms of the concentration of CA in the
brain parenchyma (and jaw muscles) using the precontrast T1 map






ICP-MS of Platinum and Gadolinium
The rats were anesthetized with isoflurane (2%), and either the
external carotid artery or the caudal vein was canulated. A
mixture of Magnevist (143 mM) and Carboplatin (5 mg/ml/rat;
20 mg/kg) including or not NG29 (i.a.: 250 nmol/kg or i.v.:
5 mmol/kg), was given in a single 1-ml infusion over 15 min. Five
minutes after the end of the infusion, anesthetized rats were
euthanized by transection of vena cava followed by an intra-
cardiac injection of saline (100 ml) in order to flush the blood from
the brain. The brain was rapidly removed and placed in
physiological saline. The tumors as well as size-related samples
of peritumoral tissue and matched tissue located in contralateral
hemisphere were resected. These samples were weighed and
digested in 2 ml of hydrogen peroxyde (30%)/nitric acid solution
for 24 h. Gadolinium (Gd) and platinum (Pt) levels were then
measured by inductively coupled plasma-mass spectroscopy (ICP-
MS; Elan DRC II, Perkin Elmer).
Assessment of Vascular Permeability to Albumin
A direct immunohistochemical technique was used for endog-
enous albumin staining in the evaluation of BBB permeability with
i.c. NG29 (see BTB disruption procedure). Slides with 5-mm
sections were equilibrated in Tris-buffered saline-0.1% Tween 20
(TBS-T, pH 7.6) for 10 min. They were then incubated with HRP
conjugated-sheep anti-rat albumin (Accurate Chemical and
Scientific Corporation) diluted 1:50 in TBS-T overnight at 4uC.
After extensive washing, Diaminobenzidine (DAB) (Roche) was
used as chromogen. Nuclei were counterstained with hematoxylin.
The specificity of the patterns observed was confirmed by
preabsorbing the antibody with a 20-fold excess (w/w) of pure
rat albumin (Accurate Chemical and Scientific Corporation).
Images of whole immunolabelled rat brain tissue sections were
acquired using a Nikon Super Coolscan 9000 ED scanner at a
resolution of 4000 dpi and analysed with ImagePro 5.1 software.
For each animal group (untreated, vehicle control and experi-
mental treated groups; n=4/group), the integrated optical density
(IOD) and surface area (mm
2) values were calculated from at least
four tissue sections per animal. Details of image acquisition,
processing and albumin quantification are provided in Meth-
ods S1.
Organ-specific NG29-induced extravasation was also assessed in
tumor-bearing animals under ketamine: xylazine anesthesia using
the semi-quantitative albumin-bound Evans blue method. Imme-
diately after i.v femoral bolus injection of Evans blue (20 mg/kg
(in 250 ml), Sigma-Aldrich), the animals were infused with a saline
or B1R agonist solution (5 mg/kg (in 500 ml)) over 15 min via a
femoral vein catheter. The animals were euthanized after 45 min.
Following a systemic perfusion with 250–300 ml of 0.9% saline to
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organ specimens (lung, pancreas, kidney, skeletal muscle, skin,
aorta, brain, heart ventricle, liver) were excised, minced, and dye
extracted by formamide (1 ml per 100 mg tissue) for 72 h. The
absorbance of Evans blue at 620 nm was measured with a
spectrophotometer (Spectra Max Plus 384, Molecular Devices).
The dye concentration in the tissue extracts was calculated from a
standard curve of Evans blue.
Vital Signs and Hemodynamic Measurements
Vital signs (respiratory rate, blood pressure, heart rate, body
temperature) and other physiological variables (hematocrit,
arterial pH) were monitored during i.a. and i.v. NG29 adminis-
tration in isoflurane-anesthetized adult F98 glioma-implanted rats.
A PE 50 catheter was inserted into the left common carotid artery
to continuously monitor the mean arterial pressure and the hearth
rate with a Micro-Med transducer (model TDX-300) connected to
a blood pressure Micro-Med analyzer (model BPA-100c). Blood
samples were withdrawn from a catheter inserted in the left
femoral artery to monitor both hematocrit and pH levels.
Statistical Analysis
Results are expressed as means 6 standard error of the mean
(S.E.M.) for the specified number (n) of animal tested. Statistical
comparisons were analyzed by one-way ANOVA followed by
Dunnett’s post hoc test or Student’s t test for unpaired observation
when appropriate. P values less than 0.05 were considered
statistically significant.
Supporting Information
Figure S1 IL-1b immunoreactivity in intracranial F98
glioma tissue samples. IHC analysis was performed 10 days
after F98 glioma cells were cerebrally implanted in Fischer rats. 3-
mm-thick sections from formalin-fixed, paraffin embedded F98-
implanted rat brains were submitted to IHC staining using rabbit
anti-rat IL-1b antibody (1:100; AAR15G AbD Serotec) as
described in Materials and Methods. Representative photomicro-
graphs of implanted (left and middle panels) and contralateral
(right panel) rat brain hemispheres showing strong immunoreac-
tivity for IL-1b within the main tumor and satellite nodules.
Magnification as indicated.
(TIF)
Figure S2 Specificity of staining with different anti-B1R
antibodies assessed by Western blotting. 50 mg of protein
extracts from glioma biopsie specimens (Grade III or IV) were
separeted by 9% PAGE and transblotted onto PVDF membranes.
Comparative immunodetection of human B1R was performed
using rabbit polyclonal anti-B1R antibodies AS434 (from W.
Mu ¨ller-Esterl, Germany), RC72 (from R. Couture, Universite ´d e
Montre ´al) or LS-A799 (LifeSpan, BioSciences); final dilutions
indicated in parenthesis. All three antibodies detected a major
immunoreactive band around 45 kDa. The appearance of other
B1R immunoreactive bands on autoradiograms of glioma samples
upon longer film exposure suggest that B1R may exist in many
post-translational molecular forms. No immunoreactivity was
found when membranes were exposed to preimmune serum (right
panel). Representative autoradiograms of two independent
experiments.
(TIF)
Figure S3 Collateral consequences of the modulation of
BTB permeability with kinin B1R and B2R agonists. In
vivo experiments were conducted under the same experimental
conditions as those described for the MRI imaging protocole. The
synthetic kinin B2R agonist R523 ([Phe
8y(CH2NH)Arg
9]-BK) or
B1R agonist NG29 (50 nmol/kg/min for 5 min) were i.c.
administered in the intracranial F98 glioma-implanted rats. (A)
Histographic representation of Gadomer uptake (mM) in the
contralateral hemispheres and jaw muscles. (B) Histographic
representation of respiratory rate (breaths/min). *p,0.05,
***p,0.001 versus CTL or vehicle groups. Value represents the
mean 6 S.E.M obtained with 6 animals. (C) Polygraphic (upper)
and histographic (bottom) representation of systemic arterial blood
pressure (mmHg). ***p,0.001 versus vehicle groups. Value
represents the mean 6 S.E.M obtained with 9 animals. Note the
appearance of severe undesired effects (non-specific permeability
induction and disturbance of respiratory function (A; left and right
panels), and hypotension (B)) only with use of R523 at equimolar
doses of agonists.
(TIF)
Figure S4 NG29-mediated local BTB disruption in a
syngeneic rat model of intracerebral metastatic breast
cancer. Fisher 344 rats were implanted intracranially with
MatBIII rat breast cancer cells (1610
4 cells/5 ml) as described
in Ref. [57]. This rat mammary carcinoma cell line expressed
transcripts and proteins of B1R as determined by RT-PCR and
WB analyses (data not shown). (A) MRI-contrast based detection
of the metastatic tumor in a rat brain at day 10 post-inoculation.
The presence of the tumor is shown on T1-weighted images of
sections 6 and 7 (white arrows). (B) Representative axial Magnevist
(Gd-DTPA)-enhanced T1-weighted MR images depicting the
brain of a MatBIII tumor-bearing rat before and after NG29
treatment (10 nmol/kg/min for 5 min i.c.) (left panels). Note the
increase in the signal intensity at the tumor (white arrows). CADV
in function of time calculated from the corresponding sets of
images (right panel). (C) Representative time course of Magnevist
(Gd-DTPA) uptake in the ipsilateral (tumor-implanted) and the
contralateral hemispheres, before and after treatment with i.c.
NG29 (10 nmol/kg/min for 5 min). Histographic representation
of average maximal Gd-DTPA concentrations (mM) in the
ipsilateral (tumor-implanted) and the contralateral hemispheres
following i.c. saline vehicle or NG29 treatment (10 nmol/kg/min
for 5 min)). *p,0.05 compared to vehicle-treated ipsilateral
groups. Value represents the mean 6 S.E.M. obtained with 3
animals.
(TIF)
Figure S5 NG29 does not modulate proliferation/
growth rate of F98 glioma cells both in vitro and in vivo.
(A) Cell proliferation assay on F98 cells was determined with
colorimetric MTT and Cristal violet assays, as described in Ref.
[74]. Cells were seeded in a 96 wells plate at 2,000 cells/well in
DMEM media supplemented with 10% FBS for 24 h at 37uC.
Cells were then incubated with and without LDBK or NG29
(10 mM) for the indicated times. Data are means 6 s.e.m. of 5 to 8
experiments. (B) Kaplan-Meier survival curves for F98-glioma-
bearing rats after systemic treatment with NG29. NG29
(250 nmol/kg i.c; 5 mmol/kg i.v.) or saline 0.9% was infused over
a period of 2 min (250 ml/min) via either the right external carotid
or the tail caudal vein. Arrows indicate time of treatment. Note
that there are two cycles of treatment for intravenous NG29 on
days 7 and 9 after implantation. Survival times, used as an indirect
measure of tumor growth, were calculated using the Kaplan-Meier
estimation by using the log-rank method in the GraphPad Prism
5.0 software. The median survival times of the vehicle- and NG29-
treated groups were similar following intra-arterial (23.5 (n=8)
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(TIF)
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